TY - JOUR
AU - Nakagawa, Kazuhiko
AB - ObjectiveThe optimal management of elderly patients with limited-disease small cell lung cancer (LD-SCLC) has not been established.MethodsThe records of elderly (70 years of age) patients with LD-SCLC who had been treated with etoposide and cisplatin chemotherapy with early concurrent twice-daily thoracic radiotherapy (TRT) were reviewed retrospectively.ResultsOf the 25 elderly patients with LD-SCLC identified, 12 (48) individuals received etoposidecisplatin chemotherapy with early concurrent twice-daily TRT. The main toxicities of this treatment regimen were hematologic, with neutropenia of Grade 4 being observed in all patients and febrile neutropenia of Grade 3 in eight patients during the first cycle of chemoradiotherapy. The toxicity of TRT was acceptable, with all patients completing the planned radiotherapy within a median of 29 days (range, 1933). No treatment-related deaths were observed. The median progression-free survival and overall survival times were 14.2 months (95 confidence interval, 4.318.2) and 24.1 months (95 confidence interval, 11.327.2), respectively.ConclusionsEtoposidecisplatin chemotherapy with early concurrent twice-daily TRT was highly myelotoxic in elderly patients with LD-SCLC, although no treatment-related deaths were observed in our cohort. Prospective studies are required to establish the optimal schedule and dose of chemotherapy and TRT in such patients.
TI - Cisplatin and Etoposide Chemotherapy Combined with Early Concurrent Twice-daily Thoracic Radiotherapy for Limited-disease Small Cell Lung Cancer in Elderly Patients
JO - Japanese Journal of Clinical Oncology
DO - 10.1093/jjco/hyp137
DA - 2010-01-16
UR - https://www.deepdyve.com/lp/oxford-university-press/cisplatin-and-etoposide-chemotherapy-combined-with-early-concurrent-MOIAw2VQe3
SP - 54
EP - 59
VL - 40
IS - 1
DP - DeepDyve
ER -